Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Builds Sales On Smoking Cessation, Eyes Prilosec OTC In 2007

This article was originally published in The Tan Sheet

Executive Summary

Pursuit of private-label omeprazole for a possible 2007 launch fits Perrigo's ongoing strategy of focusing on new products to drive sales growth

You may also be interested in...



Employers Could Be Hot Target For OTC Smoking-Cessation Sales – Survey

Drug companies offering smoking-cessation products could stoke their sales by marketing to U.S. businesses, results of a Pfizer-sponsored survey show

Employers Could Be Hot Target For OTC Smoking-Cessation Sales – Survey

Drug companies offering smoking-cessation products could stoke their sales by marketing to U.S. businesses, results of a Pfizer-sponsored survey show

Employers Could Be Hot Target For OTC Smoking-Cessation Sales – Survey

Drug companies offering smoking-cessation products could stoke their sales by marketing to U.S. businesses, results of a Pfizer-sponsored survey show

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel